ArticleEuropean journal of clinical pharmacology2008
Prevalence and patterns of methylphenidate use in French children and adolescents.
Article in European journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- Medicine and supplement use in infants, children, and adolescents depends on sex, age, and socioeconomic status: results of a German longitudinal population-based cohort study (LIFE Child).European journal of pediatrics · 2022Article
- ADHD diagnosis and methylphenidate consumption in children and adolescents: A systematic analysis of health databases in France over the period 2010-2019.Frontiers in psychiatry · 2022Article
- Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Systematic Scoping Review.JAMA network open · 2021Article
- Patterns and profiles of methylphenidate use both in children and adults.British journal of clinical pharmacology · 2018Observational
- Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence.BMJ open · 2016Article
- Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013.European child & adolescent psychiatry · 2015Article
- Recent international trends in psychotropic medication prescriptions for children and adolescents.European child & adolescent psychiatry · 2015Review
- Methylphenidate off-label use and safety.SpringerPlus · 2014Article
- Pediatric psychopharmacology: Too much and too little.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2013Article
- Prescription drug dispensing profiles for one million children: a population-based analysis.European journal of clinical pharmacology · 2013Article
- Comorbidities in ADHD children treated with methylphenidate: a database study.BMC psychiatry · 2013Article
- Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.CNS drugs · 2012Review
- Childhood attention problems and socioeconomic status in adulthood: 18-year follow-up.The British journal of psychiatry : the journal of mental science · 2012Article
- Comparison of Two brands of Methylphenidate (Stimdate(®) vs. Ritalin(®)) in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial.Iranian journal of psychiatry and behavioral sciences · 2012Article
- Article
- The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.Deutsches Arzteblatt international · 2010Article
- A three-country comparison of psychotropic medication prevalence in youth.Child and adolescent psychiatry and mental health · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of the study was to describe the prevalence and utilization patterns of methylphenidate (MPH) in children and adolescents in France.
methodsThis was a population-based retrospective study in which the cohort consisted of patients for whom data were extracted from the dispensation drug claims database of the national health insurance (NHI) fund for self-employed workers. Annual prevalence of MPH use was evaluated on patients aged 6-18 years who were reimbursed for at least one MPH prescription a year. Between January 2004 and June 2005, features of MPH medication and user profile were described for the "new starters" having a screening period of 1 year without receiving a MPH prescription and a follow-up >or=12 months. Time to interruption of MPH regular use was analysed by Kaplan-Meier survival analysis. Mean duration of exposure to MPH treatment was computed with the 95% confidence interval (CI).
resultsAnnual prevalence of MPH per 1000 persons was 1.1 in 2003, 1.5 in 2004 and 1.8 in 2005 (relative increase of 63.5%). New starters (n = 447) received their first MPH prescription through the hospital (65.1%) or through private practitioners (34.9%). The user profiles were: short (16.6%), occasional (33.8%) and regular (49.6%). Among the new starters, the median time to interruption of MPH regular use was 10.2 months (95% CI: 7.9-12.4). The mean duration of exposure to MPH treatment was: occasional (4.9 months, 95% CI: 4.3-5.5) and regular (25.7 months, 95% CI: 24.6-26.8).
conclusionAlthough there is a low prevalence of MPH use in France, this survey revealed a wide profile of users and heterogeneous use patterns.
Indexed as
Identifiers
18026941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.